Identification of critical residues of influenza neuraminidase in viral particle release by Tisoncik, Jennifer R et al.
RESEARCH Open Access
Identification of critical residues of influenza
neuraminidase in viral particle release
Jennifer R Tisoncik
1, Ying Guo
2, Katie S Cordero
1, Jia Yu
3, Jianwei Wang
4, Youjia Cao
3, Lijun Rong
1*
Abstract
Background: Influenza neuraminidase (NA) is essential for virus release from its host cells and it is one of the
targets for structure-based antiviral drug design.
Results: In this report, we established a pseudoviral particle release assay to study NA function, which is based on
lentiviral particles pseudotyped with influenza glycoproteins HA and NA as a surrogate system. Through an
extensive molecular analysis, we sought to characterize important residues governing NA function. We identified
five residues of NA, 234, 241, 257, 286 and 345, four of which (except 345) map away from the active site of NA
when projected onto the three-dimensional structure of avian influenza H5N1 NA, and substitutions of these
residues adversely affected the NA-mediated viral particle release, suggesting that these residues are critical for NA
enzymatic activity.
Conclusion: Through extensive chimeric and mutational analyses, we have identified several residues, which map
away from the active site and are critical for NA function. These findings provide new insights into NA-mediated
pseudoviral particle release and may have important implications in drug design and therapeutics against influenza
infection.
Background
Influenza virus causes acute respiratory infections result-
ing in an estimated 300,000 deaths worldwide each year,
of which approximately 36,000 deaths occur in the Uni-
ted States alone. Equally concerning is the emergence of
new viral strains in the human population, including the
ongoing H5N1 epizootic and swine-origin H1N1 pan-
demic [1-8]. While influenza vaccines are available, they
must be reformulated annually to control for antigenic
drift and shift of the two major envelope glycoproteins,
hemagglutinin (HA) and neuraminidase (NA). HA binds
N-acetyl neuraminic acid (Neu5Ac) mediating virus
entry, whereas NA catalyzes Neu5Ac receptor removal
facilitating viral particle release. The abundance of
Neu5Ac on the cellular surface can impede influenza
egress making NA critical for sustained virus infection.
NA is one example where an enveloped virus has
evolved a mechanism to promote influenza virus release,
making optimal influenza virus spread and infection
[9,10].
Several other roles have been proposed for NA includ-
ing (1) clearance of ‘decoy’ receptors within the respira-
tory mucin [11], (2) reduction of viral superinfection
[12], and (3) enhancement of viral infectivity [13,14].
NA may also enhance viral infectivity by sequestering
plasminogen to facilitate activation of HA; however, this
function may be virus specific as a recent study invol-
ving the 1918 NA does not support this notion [13-15].
It is interesting to note that, in the absence of efficient
NA activity, progeny virions aggregate at the cell sur-
face; however, a release-competent mutant lacking the
NA active site was the result of decreased HA binding
to Neu5Ac receptors. Thus, there appears to exist a bal-
ance of NA and HA activities in orchestrating viral par-
ticle release [16-18].
NA exists as a tetramer of identical subunits, each
monomer containing an active site that is highly con-
served across all influenza A and B viruses [19]. In addi-
tion to its enzymatic activity, NA has important
modifications that have been shown to influence viral
infectivity and possibly glycoprotein function [20].
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to induce neurovirulence in mice [13,21]. The NA stalk
length has also been demonstrated to be important for
enhanced pathogenicity of H5N1 virus [22,23]. Outside
of the well characterized active site, few have sought to
identify and define important residues of NA. Since NA
is one of the two major antigenic glycoproteins of influ-
enza virus, and it is a good target of drug therapeutics,
we sought to further characterize the role of NA in this
study. Through extensive chimeric and mutational ana-
lyses, we have identified several residues, which map
away from the active site and are critical for NA func-
tion in viral particle release. These findings provide new
insights into NA-mediated pseudoviral particle release
and may have important implications in drug design
and therapeutics against influenza infection.
Results
Characterization of influenza NA using HIV/HA
pseudotype particles
Reporter-based HIV/HA pseudotyped viruses were gen-
erated by co-transfection of HA and env-deficient HIV-1
plasmids into 293T producer cells [24]. The human
293T and A549 target cells were challenged with the
producer cell culture supernatants collected 48 h post-
transfection and transduction determined by luciferase
activity in the target cells. Addition of soluble NA to the
culture medium during pseudovirion production
enhanced HIV/HA transduction (Figure 1A). Co-trans-
fection of NA from mouse-adapted human virus (PR8),
henceforth referred to as NAH,w i t ht h eH Aa n dH I V
plasmids resulted in greater transduction efficiency, 1.7
×1 0
7 and 6.8 × 10
6 RLU for 293T and A549 cells,
respectively. In contrast, co-transfection of NA from an
avian H5N1 virus (NAA) resulted in luciferase levels
only slightly higher than the background level, 1.3 × 10
3
and 1.3 × 10
2 RLU for 293T and A549 cells, respectively
(Figure 1A).
A hemagglutination assay was used to further explore
the discrepancy between NAH and NAA-mediated pseu-
dovirus production. As shown in Figure 1B, pseudovir-
ions produced in the presence of NAH resulted in a
hemagglutination titer of 32 HA units/ml, while expres-
sion of NAA resulted in no hemagglutination, similar to
the PBS control. The supernatants derived from co-
transfections with HIV vector and NAH alone, or with
HIV vector, NAH and VSV-G, the glycoprotein of vesi-
cular stomatitis virus, resulted in no hemagglutination
(results not shown). These results correlate with the
luciferase data, further suggesting that NAA is deficient
in mediating pseudovirion release from the 293T produ-
cer cell surface. To determine if the defect was related
to its enzyme activity, NA catalysis of fluorogenic sub-
strate (4-MUNANA) was measured. Compared to NAH,
Figure 1 Characterization of HIV/HA pseudoviral particle release
mediated by NAA and NAH. A, relative infectivity of the pseudovirions
determined by luciferase activity (relative light units, RLUs) from
infected 293T and A549 target cells. Pseudovirions generated in the
absence of NA represent background luciferase levels. As a positive
control, HA and HIV plasmids were first introduced into 293T producer
cells and the transfected cells were then treated with a commercial
neuraminidase twice during pseudovirion production (+bNA).
Experiments were performed in triplicates and repeated several times.
Error bars indicate standard deviations. B, hemagglutination activity
from titrated NAA and NAH pseudovirion populations mixed with
chicken red blood cells. PBS serves as a negative control. C,
neuraminidase activity of NAA and NAH proteins measured by the
release of fluorogenic substrate 4-MUNANA (arbitrary units).
Experiments were performed in triplicates and repeated several times,
and error bars indicate standard deviations.
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matic activity (Figure 1C). This may be the result of
defective viral genes despite NAA being derived from an
avian H5N1 virus, or through PCR introduced muta-
tions or both. Nevertheless, we reasoned this defective
NA clone could allow us to identify critical residues of
NA which had not been identified previously.
Functional analysis of NAH/NAA chimeric constructs
Comparison of NAA and NAH primary sequences
revealed 83% amino acid identity with a total of 81
amino acid differences (Figure 2A). All the residues pre-
viously identified to be important for NA function are
identical for these genes with the exception of position
119. Thus, additional residues of NA likely play an
important role in NA activity. To delineate the region(s)
critical for NA-mediated pseudovirion release, a panel of
six chimeric NA constructs was generated and charac-
terized in the luciferase assay (Figure 2B). Chimeric pro-
tein NAC (NAA 176-230) behaved like parental NAH
resulting in 1.6 × 10
7 RLU (Figure 2B). Additionally,
hemagglutination and NA enzyme activity of NAC (NAA
176-230) was comparable to NAH and consistent with
the luciferase data (Table 1). Within this region, aa 176-
230, there are five variable residues between the two
NAs (Figure 2B), and therefore the differences in this
region are not important for NA activity. NA chimeric
constructs NAC (NAA 1-230) and NAC (NAA 88-230)
displayed reduced luciferase levels and enzyme activity,
as well as a complete loss of hemagglutination (Figure
2B, and Table 1). Similarly, chimeric proteins NAC
(NAA 226-301), NAC (NAA 226-362) and NAC (NAA
226-470) all resulted in a complete loss of NA function.
We conclude that variations in the N-terminus of NAA,
aa 88-176, and the C-terminal portion aa226-301 contri-
bute toward the defective NAH phenotype (Figure 2B,
Table 1).
To identify the critical residue(s) for NA function, we
took a gain-of-function approach and systematically sub-
stituted the variable residues within aa regions 88-176
(Table 1) and 226-301 of NAC (NAA 88-230) and NAC
(NAA 226-301), respectively (Figure 3A and Table 1).
For example, tyrosine 234 in NAC (NAA 226-301) was
substituted to an asparagine (NAC Y234N), the existing
NAH residue corresponding at this position. For NAC
(NAA 226-301), a total of ten, either single or combined,
substitutions were generated (Figure 3A). Three substi-
tutions introduced within NAC (NAA 226-301), Y234N,
M257I, and E286K, resulted in increased luciferase activ-
ity, hemagglutination and NA enzyme activity, as com-
pared to NAC (NAA 226-301) (Figure 3B-D). Y234N
gave 32 HA units/ml, M257I resulted in 8 HA units/ml
and HA activity for E286K was observed with the undi-
luted (Und) sample (Figure 3C). These results were
generally in agreement with the enzymatic data. How-
ever, we did not observe a strong correlation between
the magnitude of the HA and the magnitude of the
infectivity as measured by the luciferase assay. For
example, mutant Y234N displayed higher HA activity
than E286K (32 vs undiluted), but it gave a lower level
of infectivity than that of E286 (also see Table 1). The
nature of this discrepancy needs to be further examined
in the future.
The NAC (NAA 226-301) constructs with Y234N,
M257I, and E286K substitutions resulted in increased
levels of NA activity (Figure 3D). Taken together, these
results indicate that N234, I257, and K286 of NAH are
critical for NA activity and hence function in pseudo-
viral particle release. Using the same approach, we also
demonstrated a critical role of E119 within NAC (NAA
88-230) for enzyme activity (Table 1).
To further examine the potential role of these resi-
dues of NA, N234Y, I257M, and K286E substitutions,
single or combined, were introduced into NAH.T h e
single NAH substitutions marginally effected NA func-
tion. NAH double substitution mutants, N234Y/I257M,
N234Y/K286E and I257M/K286E, completely abol-
ished NA activity (Figure 4A-C, and Table 1). Interest-
ingly, NAH triple substitution mutant resulted in a
revertant phenotype. Its enzymatic activity was com-
parable to NAH, and it displayed restored luciferase
levels and partially restored hemagglutination (Figure
4a n dT a b l e1 ) .
All NA mutants were expressed in the producer cells.
NAH N234Y and all three double substitution mutants
migrated faster than NAH on the SDS-PAGE gel (Figure
4D, left panel). the double substitution NA mutants
were not expressed on pseudoviral particles (Figure 4D,
right panel). The triple NA mutant showed a similar
migration pattern to NAH and it was expressed on pseu-
dovirions (Figure 4D, right panel). These data correlated
with the NAH triple mutant restored activity.
Identification of critical residues for NA function
An NAA variant derived from the A/chicken/Henan/
2004 (H5N1) mRNA, henceforth referred to as NAA*,
was generated and displayed an intermediate phenotype
in NA function. NAA* resulted in a hemagglutination
titer of 8 HA units/ml and enhanced enzyme activity
compared to NAA (Figure 5B, Table 1). Sequence align-
ment indicated that NAA* contains six amino acid differ-
ences from NAA. Isoleucine at position 8 of NAA* is
located in the transmembrane domain, and differs from
Thr8 of NAA. The remaining five NAA* residues, E119,
N234, M241, G248 and G345, which are conserved with
NAH at the corresponding positions, but differ from
that of NAA (V119, Y234, R241, W248 and R345) are
located in the ectodomain of the protein.
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we first took a gain-of-function approach to determine
which amino acid substitutions were required to restore
NAA function. Since NAH substitution mutant G248W
was comparable to NAH (see Table 1), we focused on the
following residues of NAA, V119, Y234, R241 and R345.
As shown in Figure 6, all four substitutions in combina-
tion were required to restore NAA to a level comparable
to NAA*. These results demonstrated that these four resi-
dues are critical in maintaining NA activity.
Figure 2 Alignment of NAA and NAH amino acid sequences and schematic of NA constructs. A, amino acid sequence alignment of full-
length NAA and NAH proteins. Residue differences are shaded and deletions in the NAH linear sequence are denoted by (-) symbol. B, schematic
of full-length NAA and NAH proteins and chimeric NA protein panel (NAC). NAH sequence is colored red and NAA sequence is colored yellow.
The NAA regions represented in NA chimeric proteins are labeled according to N2 numbering. The luciferase activities from infected 293T cells
are shown on the right. Values are presented as the average of triplicate samples (± SD).
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Page 4 of 14Table 1 Summary of HIV/HA-mediated relative infectivity and HA and NA activity
NA construct Luciferase activityª HA U/ml 4-MUNANA Release (a.u.)
293T cells A549 cells
NAH 1.7 (±0.03) × 10
7 6.9 (±0.5) × 10
6 64 9.3 (±0.41) × 10
4
E119V 8.1 (±2.10) × 10
5 1.2 (±0.1) × 10
3 0 8.3 (±0.51) × 10
3
N234Y 1.7 (±0.02) × 10
6 4.3 (±1.00) × 10
5 16 2.5 (±0.04) × 10
4
M241R 2.7 (±0.10) × 10
5 1.6 (±1.1) × 10
2 0 4.9 (±0.16) × 10
2
G248W 9.1 (±10.3) × 10
6 7.5 (±1.7) × 10
5 32 2.8 (±0.11) × 10
4
G345R 3.7 (±0.90) × 10
4 1.3 (±)0.3 × 10
2 0 4.1 (±0.25) × 10
2
I257M 1.8 (±0.009) × 10
7 4.6 (±0.47) × 10
6 64 8.3 (±0.29) × 10
4
K286E 1.4 (±0.02) × 10
7 1.5 (±0.27) × 10
6 32 7.9 (±0.38) × 10
4
N234Y/I257M 4.1 (±1.9) × 10
3 3.5 (±4.7) × 10
2 0 1.6 (±0.24) × 10
4
N234Y/K286E 1.6 (±0.11) × 10
5 1.1 (±0.22) × 10
4 0 2.1 (±0.32) × 10
4
I257M/K286E 9.8 (±0.29) × 10
3 1.2 (±0.17) × 10
4 0 1.0 (±0.10) × 10
4
N234Y/I257M/K286E 4.3 (±0.49) × 10
6 4.7 (±0.56) × 10
6 8 7.0 (±0.37) × 10
4
NAA* 6.9 (±1.4) × 10
5 6.7 (±1.5) × 10
5 2 1.7 (±0.26) × 10
3
No NA 1.3 (±0.9) × 10
3 1.3 (±0.7) × 10
2 0 4.3 (±0.1) × 10
2
NAA 1.0 (±0.57) × 10
4 4.9 (±3.4) × 10
2 0 6.0 (±0.27) × 10
2
V119E 5.4 (±0.6) × 10
3 7.0 (±6.6) × 10
2 0 6.7 (±0.31) × 10
2
Y234N 1.3 (±0.2) × 10
4 7.3 (±4.9) × 10
2 0 4.2 (±0.27) × 10
2
R241M 1.2 (±0.2) × 10
4 9.7 (±5.1) × 10
2 0 4.4 (±0.12) × 10
2
R345G 1.3 (±0.1) × 10
4 7.8 (±2.2) × 10
2 0 4.3 (±0.42) × 10
2
V119E/Y234N 9.1 (±2.9) × 10
3 6.9 (±3.9) × 10
2 0 4.6 (±0.14) × 10
2
V119E/R241M 1.1 (±0.3) × 10
4 5.7 (±1.3) × 10
2 0 4.0 (±0.04) × 10
2
V119E/R345G 1.2 (±0.1) × 10
4 5.0 (±0.6) × 10
2 0 4.2 (±0.16) × 10
2
Y234N/R241M 7.5 (±3.0) × 10
3 1.5 (±1.0) × 10
3 0 4.2 (±0.16) × 10
2
Y234N/R345G 8.2 (±2.8) × 10
3 1.1 (±0.9) × 10
3 0 4.3 (±0.10) × 10
2
R241M/R345G 1.8 (±0.2) × 10
4 1.7 (±0.8) × 10
3 0 8.2 (±0.47) × 10
2
V119E/Y234N/R241M 1.0 (±0.05) × 10
4 2.8 (±1.2) × 10
2 0 4.2 (±0.23) × 10
2
V119E/Y234N/R345G 1.0 (±0.3) × 10
4 3.3 (±1.8) × 10
2 0 4.4 (±0.29) × 10
2
V119E/R241M/R345G 2.1 (±0.25) × 10
5 1.1 (±0.1) × 10
4 0 5.4 (±0.09) × 10
2
Y234N/R241M/R345G ND ND ND ND
V119E/Y234N/R241M/R345G 2.5 (±0.6) × 10
6 1.5 (±0.1) × 10
6 2 2.7 (±0.99) × 10
3
NAC (NAA 176-230) 1.6 (±0.05) × 10
7 3.0 (±0.57) × 10
6 64 5.5 (±0.08) × 10
4
NAC (NAA 88-230) 5.0 (±0.50) × 10
5 1.9 (±0.58) × 10
4 0 2.3 (±0.07) × 10
4
NAC (NAA 1-230) 1.6 (±0.39) × 10
5 6.8 (±2.1) × 10
3 0 4.5 (±0.10) × 10
3
S95R 4.3 (±0.07) × 10
5 1.9 (±0.5) × 10
4 0 2.1 (±0.12) × 10
4
V99I/H100Y 5.9 (±0.6) × 10
5 2.6 (±0.1) × 10
4 0 3.1 (±0.03) × 10
4
V119E 1.4 (±0.08) × 10
7 2.1 (±0.1) × 10
6 16 3.0 (±0.09) × 10
4
N146S 1.5 (±0.2) × 10
5 7.0 (±1.5) × 10
3 0 1.1 (±0.02) × 10
4
H155Y/T157A 3.8 (±0.8) × 10
5 2.4 (±0.3) × 10
4 0 2.0 (±0.06) × 10
4
NAC (NAA 226-470) 1.3 (±0.35) × 10
4 1.1 (±0.5) × 10
3 0 4.0 (±0.09) × 10
2
NAC (NAA 226-362) 1.1 (±0.50) × 10
4 1.4 (±0.5) × 10
4 0 4.3 (±0.02) × 10
2
NAC (NAA 226-301) 1.2 (±0.09) × 10
5 2.5 (±0.7) × 10
3 0 1.3 (±0.02) × 10
3
Y234N 7.2 (±0.56) × 10
6 3.6 (±0.3) × 10
5 32 1.5 (±0.04) × 10
4
N247D/W248G/Q249L 1.0 (±0.31) × 10
6 6.2 (±2.6) × 10
3 0 1.5 (±0.09) × 10
3
M257I 7.1 (±1.37) × 10
6 6.0 (±1.0) × 10
4 4 1.2 (±0.01) × 10
4
V263T/V266I 6.5 (±0.80) × 10
4 1.1 (±0.6) × 10
3 0 4.8 (±0.37) × 10
2
E269N 2.5 (±0.52) × 10
5 6.4 (±3.0) × 10
3 0 1.1 (±0.07) × 10
3
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mine which amino acid substitutions adversely affected
the function of NAH. Substitutions E119V, M241R and
G345R abolished NAH activity whereas substitution
N234Y resulted in a moderate reduction in NA enzyme
activity and luciferase levels from target cells. In con-
trast, substitution G248W did not adversely affect the
NA-mediated HIV pseudovirus release (Figure 6A and
6C, and Table 1). In general, these results were consis-
tent with that of the HA assay (Figure 6B and Table 1).
NAH substitution mutants M241R, G345R and E119V
resulted in no hemagglutinating virions, while the HA
titer of NAH G248W was comparable to parental NAH
and NAH N234Y resulted in 16 HA units/ml. Thus,
these results indicate that two additional residues (M241
and G345) are also critical for NAH activity. All NA
mutants were expressed in producer cell lysates and in
pseudovirion lysates with the exception of NAH
mutants, M241R and G345R (Figure 6D). To ensure
that the mutations did not adversely affect NA folding
or transport, we evaluated NA cellular surface expres-
sion using a biotinylation assay. It was found that NAH
single and combined substitutions did not disrupt the
capacity for NA to be properly folded and transported
to the plasma membrane. All NA mutants in this panel
were detected on the surface and showed comparable
expression levels (data not shown). Hence, the defective
NA function observed with NAH double substitution
mutants and NAH M241R and G345R single mutants is
not a result of reduced cell surface expression levels.
Discussion
In this study, we sought to identify important residues
for influenza virus NA function. Previous reports have
identified numerous critical residues forming the NA
enzyme active site and surrounding framework (in N2
numbering): Arg 118, Glu 119, Asp 151, Arg 152, Asp
198, Ile 222, Arg 224, Glu 227, Asp 243, His 274, Glu
276, Glu 277, Arg 292, and Asp 330, Arg 371
[19,25-28]. The goal of the current work was to further
examine and identify additional critical residues of NA
using an established pseudotyping system to study influ-
enza virus envelope glycoprotein function [24]. We
demonstrated HIV/HA pseudovirion production may be
used as a suitable surrogate system to indirectly measure
viral particle release from 293T producer cells. Through
an extensive molecular analysis, we identified and char-
acterized critical molecular determinants at the follow-
ing five positions: 234, 241, 257, 286 and 345 In
mapping these positions onto the three-dimensional
structure of avian H5N1 NA, we found that these resi-
dues, with the exception of G345, are distal to the active
site (Figure 7). Internal residues, M241 and M257, are
part of b-sheet 3, while residues 234 and 286 are surface
exposed and localize more closely together on the ecto-
domain surface proximal to the virion membrane. G345
is part of an antigenic site (aa 339-347) located on the
rim of the enzyme pocket. Sequence alignment of over
8,000 NAs revealed greatest amino acid variability at
positions 257 and 286 and to a lesser extent at position
234. In contrast, M241 and G345 are highly conserved
with a very low frequency of amino acid variations
observed at these two positions.
This study was initiated when it was observed that
two NA genes demonstrated distinct phenotypes. An
NA gene derived from mouse-adapted PR8 influenza
virus (NAH) could efficiently facilitate release of HIV/
HA pseudovirions from the producer cells, whereas an
avian H5N1 NA clone (NAA) was completely defective.
By creating a panel of chimeric constructs between
these two genes, we were able to identify two regions of
NA, aa regions 88-176 and 226-301, likely responsible
for the functional difference of these two NAs (see Fig-
ure 2). Mutational analysis of these regions led to identi-
fication of critical molecular determinants at positions
234, 257 and 286. We also identified residues 241 and
345, and further confirmed the importance of residue
234 by restoring NAA activity. Introduction of arginine
at either position 241 or 345 completely abrogated NA
function; however, NAH M241R and G345R mutants
were detected on the cells surface through biotinylation.
Hence, the defective NA function observed with NAH
M241R and G345R single mutants is not a result of
reduced expression on the cell surface.
Viral envelope modifications, including glycosylation
patterns, may dictate, in part, viral glycoprotein function.
Table 1 Summary of HIV/HA-mediated relative infectivity and HA and NA activity (Continued)
Y273S 1.2 (±0.07) × 10
5 2.9 (±0.6) × 10
3 0 5.0 (±0.26) × 10
2
A284T 1.0 (±0.08) × 10
5 2.6 (±1.0) × 10
3 0 6.2 (±0.15) × 10
2
E286K 1.8 (±0.004) × 10
7 2.2 (±0.1) × 10
6 Und 1.6 (±0.04) × 10
4
I287V 6.1 (±0.45) × 10
5 1.2 (±0.1) × 10
4 0 1.2 (±0.01) × 10
3
T288M 1.6 (±0.06) × 10
6 6.0 (±0.3) × 10
4 0 5.2 (±0.18) × 10
3
a All values are in relative light units (RLU). Standard errors of the means are in parentheses.
ND, not determined
Und, undiluted
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Page 6 of 14Figure 3 Molecular analysis of amino acid region 226-301 in NA function. A, schematic of NAC (NAA 226-301). NAH sequence is colored red
and NAA sequence is colored yellow. Single and combined substitutions generated in NAC (NAA 226-301) are shaded. B, relative infectivity of
293T and A549 target cells challenged with pseudovirus produced in the presence of respective NAC (NAA 226-301) mutants. Luciferase activity is
presented as fold-change. Experiments were performed in triplicates and repeated several times, and error bars indicate standard deviations. C,
hemagglutination activity of NAC (NAA 226-301) substitution panel. Pseudovirions were mixed with chicken red blood cells and HA titers
recorded. D, neuraminidase activity of NAC (NAA 226-301) substitution mutants measured by the release of fluorogenic substrate 4-MUNANA.
Experiments were performed in triplicates and repeated several times, and error bars indicate standard deviations.
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Page 7 of 14Figure 4 Characterization of critical residues necessary for NA function. A, relative infectivites of pseudovirions produced in the presence of
NAH N234Y, I257M and K286E single and combined substitution mutants (N2 numbering). Experiments were performed in triplicates and
repeated several times, and error bars indicate standard deviations. B, hemagglutination activity of NAH substitution panel. C, neuraminidase
activity of NAH substitutions measured by the release of fluorogenic substrate 4-MUNANA. Enzyme activity is presented as the fold-change of
triplicate samples. Experiments were performed in triplicates and repeated several times, and error bars indicate standard deviations. D, western
blot of HA and NA expression in 293T cell lysates and incorporation onto HIV particles. The HA precursor (HA0), and proteolytic subunits (HA1
and HA2) are detected in both cell and virus lysates.
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Page 8 of 14Figure 5 NAA gain-of-function in pseudoviral particle release. A, luciferase activity of pseudovirions generated in the presence of NAA and
NAA mutants containing single or combined substitutions V119E, Y234N, R241M and R345G (N2 numbering). Experiments were performed in
triplicates and repeated several times, and error bars indicate standard deviations. B, hemagglutination activity of NAA substitution panel. C,
neuraminidase activity of NAC (Av 226-301) substitution mutants measured by the release of fluorogenic substrate 4-MUNANA. Experiments were
performed in triplicates and repeated several times, and error bars indicate standard deviations.
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e x p o s e d( s e eF i g u r e7 )a n di sp a r to fac o n s e r v e dm o t i f
(Asn-X-Ser/Thr) that denotes an N-linked glycosylation
site. NAs containing N234Y substitution displayed a mobi-
lity shift on an SDS-PAGE gel suggesting that elimination
of this glycosylation site on NA resulted in the loss of the
carbohydrate modification. Interestingly, a similar mobility
shift was also observed with the NAH I257M/K286E dou-
ble substitution mutant that retained N234. We speculate
that this was likely due to a misfolded NA which altered
or masked the glycosylation site and prevented carbohy-
drate attachment. Glycosylation of N234 may be impor-
tant for NA activity required to mediate the release of
HA-containing HIV particles; however, like all the NA
mutants, the mutation does not affect protein expression
on the cellular surface.
It is interesting to point out that the individual substi-
tutions N234, I257 or K286 in NAH impaired NA func-
tion, but a more striking defect was observed when any
two substitutions were combined (see Figure 4). All
Figure 6 Effect of E119V, N234Y, M241R and G345R single substitutions on NAH function. A, luciferase activity of pseudovirions generated
in the presence of NAH single substitution mutants. Experiments were performed in triplicates and repeated several times, and error bars
indicate standard deviations. B, hemagglutination activity of NAH substitution panel. C, neuraminidase activity of NAH substitution mutants
measured by the release of fluorogenic substrate 4-MUNANA. Values are presented as the fold-change of triplicate samples. Experiments were
performed in triplicates and repeated several times, and error bars indicate standard deviations. D, western blot of NA expression in 293T cells
and incorporation onto HIV particles.
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Page 10 of 14three double mutants were detectable in the cell lysates,
with a faster migrating position on SDS-PAGE, but
these mutants were not detected on the cell surface
explaining their absence on the HIV pseudovirions.
However, the triple mutant behaved more like NAH,
with greatly restored NA activities. Further analysis of
the roles of these residues may provide insights on NA
structure and function. Since many of these residues are
clustered on the underside of the large globular head
when projected onto the three-dimensional structure of
avian influenza H5N1 NA. We speculate that this region
may be a unique target site on NA for the design of
novel inhibitors.
Currently, NA inhibitor oseltamivir carboxylate (Tami-
flu) is the best available drug for influenza treatment. Its
efficacy, however, is limited due its high propensity to
select for drug-resistant variants, which is becoming an
increasing problem with seasonal influenza strains. Thus,
it is important to continue efforts for the design and
development of more potent and efficacious drugs to
treat influenza infection. The region in which residues
234, 286-both of which are surface exposed and lie adja-
cent to each other on the underside of the ectodomain-
and internal residue 257 may offer a unique opportunity
to explore a new target region on NA, particularly since
we have demonstrated this region’si m p o r t a n c ei nN A
function. We believe that these assays can be adapted for
characterizing the NA function of 1918 pandemic influ-
enza virus to alleviate safety concerns. Of interest, residue
234 of H1N1 NA has been recently demonstrated to be a
“permissible” secondary mutation site which may allow
the virus to compensate for the reduced fitness of
Figure 7 Projection of critical NA residues onto the tertiary structure. A, NA monomer ribbon diagram. Tri-arginyl residues (R118, R292 and
R371) are labeled blue for reference of the enzyme active site. Residue substitution sites (N234, M241, M257, E286, and G345) are labeled red. B,
NA monomer surface representation. N234 and E286 are shown in red. C, NA tetramer surface representation. View is looking up from the virion
surface at the underside of the globular head. N234 and E286 are shown in red. D, side profile view of NA tetramer surface representation,
parallel to the viral membrane. N234 and E286 are labeled red and the active site is labeled blue. The NA structures are displayed using PyMOL
published by DeLano Scientific. PDB ID: 2HTY[34,35].
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ing the importance of the residue 234 identified as being
important in NA function.
Methods
Cell lines
Human 293T cells were maintained in Dulbecco’s modi-
fied Eagle’s Medium (DMEM; HyClone) supplemented
with 10% fetal bovine serum (FBS; HyClone), 100 μg/ml
of streptomycin and 100 units of penicillin (Invitrogen).
Human lung epithelial A549 cells were grown in Roswell
Park Memorial Institute medium (RPMI; Invitrogen)
supplemented with 10% fetal bovine serum (FBS;
HyClone), 100 μg/ml of streptomycin, 100 units of peni-
cillin (Invitrogen), 1% Na-pyruvate and 1% 1 M HEPES.
Constructs and reagents
T h eH Ag e n ei sf r o mh i g h l yp a t h o g e n i ca v i a ni n f l u e n z a
A/Goose/Qinghai/59/2005 (H5N1) virus isolated from
infected migratory waterfowl found in Lake Qinghaihu,
Qinghai Province, in western China [30]. NA cDNA from
the mouse-adapted A/Puerto Rico/8/1934 (H1N1; PR8)
influenza virus strain was kindly provided by John Olsen,
University of North Carolina [31]. The mRNA and plas-
mid borne NA gene were derived from highly pathogenic
avian influenza A/chicken/Henan/12/2004 (H5N1) virus.
The HIV-1 vector pNL4-3.Luc.R
-E
- and mouse monoclo-
nal anti-p24 HIV antibody were obtained through the
NIH AIDS Research and Reference Reagent program
(Germantown, MD). Polyclonal anti-HA (H5) NR163 was
obtained from the Biodefense and Emerging Infections
Research Resources Repository (Manassas, VA).
NA chimeric constructs were created by a two-step
PCR technique with custom designed, overlapping pri-
mers. The amplified fragments were cloned into pEF6/
V5-His-TOPO vector (Invitrogen) using KpnI and NotI
restriction enzymes and the sequence was confirmed by
DNA sequencing. Influenza virus mRNA from A/
chicken/Henan/12/2004 (H5N1) was reverse transcribed
into cDNA using primer set (5’to 3’acacggagcaaaagcagg
and acgcggagtagaaacaagg) [32]. The NA cDNA was
amplified using segment-specific primers and the result-
ing PCR product inserted into pEF6/V5-His-TOPO vec-
tor (Invitrogen). Site-directed mutagenesis of the NA
genes was performed using the Strategene Quick-
Change mutagenesis kit following the supplier’s protocol
with custom designed primers carrying the designated
mutation. All NA mutants were confirmed by DNA
sequencing of the full-length NA gene.
Production of pseudovirions and infection assay
Influenza pseudovirions were produced in 293T cells
using a polyethylenimine (PEI)-based transfection proto-
col. Plasmid DNAs were co-transfected into 293T cells
and after 48 h post-transfection, culture supernatants
were collected, filtered through a 0.45 μm-pore size filter
(Nalgene) and used to directly infect 293T and A549 tar-
get cells. Empty vector was used in place of omitted plas-
mids where appropriate. Relative infectivity was
determined 48 h post-infection by measuring luciferase
activity of the reporter gene using an FB12 luminometer
at 10 second intervals (Berthold detection system). Each
sample was done in triplicate and the experiments
repeated at least three times. For NA treatment, a com-
mercial neuraminidase (Clostridium perfringens; New
England Biolabs) was added to producer cells at 26 h and
46 h post-transfection at a concentration of 5 units/ml.
Hemagglutination assay
Producer cell culture supernatants were harvested 48 h
post-transfection, filter-sterilized and concentrated over
a 30% Sucrose-NTE cushion consisting of 100 mM
NaCl, 10 mM Tris (pH 7.4), and 1 mM EDTA by centri-
fugation at 55,000 rpm for 2 h in a SW55Ti rotor at 4°
C. Pseudovirion pellets were resuspended in 50 μlo f
Tris-buffer containing 50 mM Tris-HCl (pH 7.5), 150
mM NaCl, and 5 mM EDTA. Twofold serial dilutions
were mixed with an equal volume of 0.5% chicken ery-
throcyte suspension (CRBCs; Lampire Biological Labora-
tories) and incubated in a U-bottomed 96-well plate at
4°C. HA titers were recorded after 1 h. Hemagglutina-
tion assay experiments were repeated at least three
times.
Neuraminidase enzyme assay
A standard fluorometric enzyme assay developed by
Potier et al. was adapted to measure NA activity [33].
Producer cell lysates transfected with representative NA
constructs were added to NA fluorogenic substrate 2’-
(4-methylumbelliferyl- N-acetylneuraminic acid (4-
MUNANA; Sigma) to a final concentration of 100 μM.
The reactions were carried out in 50 μlo f3 3m MM E S
(pH 6.5) containing 4 mM CaCl2 in 96-well black Opti-
plates (BD Biosciences) and incubated in a 37°C water
bath for 1 h. The reactions were terminated by adding
150 μl stop solution containing 0.5 M NaOH (pH 10.7)
and 25% ethanol. The fluorescence of released 4-methy-
lumbelliferone was measured using a Labsystems Fluor-
oskan II spectrophotometer (PerkinElmer). The
excitation wavelength was set at 355 nm, and the emis-
sion wavelength was set at 460 nm. Samples were done
in triplicate and the experiments repeated at least three
times.
Immunoblot analysis
NA genes modified to express a C-terminal HA-epitope
t a gw e r eu s e dt oa n a l y z eN Ap r o t e i ne x p r e s s i o ni nt h e
producer cell lysates and NA incorporation onto HIV
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NA plasmids and 48 h post-transfection the cells were
washed in ice-cold PBS and then lysed in 0.2 ml of Tri-
ton X-100 lysis buffer containing 50 mM Tris-HCl (pH
7.5), 150 mM NaCl, 5 mM EDTA, 1% Triton-X, and a
protease inhibitor cocktail. The cell culture supernatants
were layered over a 20% sucrose cushion and centri-
fuged at 55,000 rpm for 45 min in a SW55Ti rotor at
16°C. The pseudovirion pellets were lysed in 1% Triton
X-100 lysis buffer, samples subjected to SDS-PAGE and
then transferred to a PVDF membrane. NA was
detected with monoclonal anti-HA antibody (Sigma)
and HIV core with monoclonal anti-p24 antibody. The
membrane was then probed with peroxidase-conjugated
goat anti-mouse secondary antibody and the protein
bands visualized by chemiluminescence (Pierce).
NA cellular surface expression
Producer cells were transfected with representative NA
plasmids and 48 h post-transfection the cells were
washed and then released in PBS (pH8.0) containing 0.5
mM EDTA. Cell surface proteins were biotinylated for
30 min at 4°C using EZ-Link™ Sulfo-NHS-LC-Biotin
reagent (Thermo Fischer Scientific). Cells were washed
twice with ice-cold PBS (pH 8.0) containing 100 mM
glycine, once with ice-cold PBS (pH 8.0), and then lysed
in Triton-X 100 lysis buffer containing a protease inhibi-
tor cocktail. Biotinylated surface proteins were separated
from cell lysates using NeutrAvidin Agarose Resin
(Thermo Fisher Scientific) by incubating mixtures over-
night at 4°C. Agarose beads were washed twice with
PBS (pH 8.0) and resuspended in PBS. Samples were
subjected to SDS-PAGE analysis and NA proteins were
detected following the immunoblot protocol described
above.
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